drugset / Trial / NCT00410046

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

NCT00410046

Phase 4 Completed 84 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.

Timeline

Start
2006-12
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous